Literature DB >> 33554715

Cutaneous, systemic features and laboratory characteristics of late- versus adult-onset systemic lupus erythematosus in 1006 Thai patients.

Kumutnart Chanprapaph1, Ittipon Tubtieng1, Nathathai Pratumchat1, Kunlawat Thadanipon2, Ploysyne Rattanakaemakorn1, Poonkiat Suchonwanit1.   

Abstract

BACKGROUND: Age at disease onset may modulate systemic lupus erythematosus (SLE), but its relation to cutaneous/extracutaneous manifestation remains understudied.
OBJECTIVE: To compare the cutaneous, systemic features, laboratory characteristics, and disease severity between late- and adult-onset SLE patients.
METHODS: Analyses of the cutaneous, systemic involvement, laboratory investigations, SLE disease activity index 2000 (SLEDAI-2K), and disease damage were performed to compare between groups.
RESULTS: Of 1006 SLE patients, 740 and 226 had adult- (15-50 years) and late-onset (>50 years), respectively. Among 782 with cutaneous lupus erythematosus (CLE), acute CLE (ACLE) and chronic CLE (CCLE) were more common in the adult- and late-onset SLE, respectively (p = 0.001). Multivariable logistic regression analysis demonstrated that male patients and skin signs, including papulosquamous subacute CLE, discoid lupus erythematosus, and lupus profundus, were associated with late-onset SLE (all p < 0.05). Late-onset SLE had lower lupus-associated autoantibodies, and systemic involvement (all p < 0.05). ACLE, CCLE, mucosal lupus, alopecia, and non-specific lupus were related to higher disease activity in adult-onset SLE (all p < 0.001). There was no difference in the damage index between the two groups.
CONCLUSIONS: Late-onset SLE had a distinct disease expression with male predominance, milder disease activity, and lower systemic involvement. Cutaneous manifestations may hold prognostic values for SLE.

Entities:  

Keywords:  Late onset-SLE; SLE; SLEDAI-2K; hematologic involvement; lupus nephritis

Year:  2021        PMID: 33554715     DOI: 10.1177/0961203321991920

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  3 in total

Review 1.  Application of Topical Immunotherapy in the Treatment of Alopecia Areata: A Review and Update.

Authors:  Thipprapai Mahasaksiri; Chaninan Kositkuljorn; Tanaporn Anuntrangsee; Poonkiat Suchonwanit
Journal:  Drug Des Devel Ther       Date:  2021-03-23       Impact factor: 4.162

2.  Incidence and Risk Factors of Hepatic Fibrosis in Psoriatic Patients Receiving Methotrexate with Concomitant Acitretin Therapy and Methotrexate Monotherapy.

Authors:  Ploysyne Rattanakaemakorn; Prinpat Pinyowiwat; Wimolsiri Iamsumang; Kumutnart Chanprapaph; Poonkiat Suchonwanit
Journal:  Drug Des Devel Ther       Date:  2021-05-28       Impact factor: 4.162

3.  Trichoscopic Signs in Dermatomyositis, Systemic Lupus Erythematosus, and Systemic Sclerosis: A Comparative Study of 150 Patients.

Authors:  Kumutnart Chanprapaph; Preeyachat Limtong; Pintip Ngamjanyaporn; Poonkiat Suchonwanit
Journal:  Dermatology       Date:  2021-12-08       Impact factor: 5.197

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.